Cost-effectiveness analysis of exenatide once-weekly versus dulaglutide, liraglutide, and lixisenatide for the treatment of type 2 diabetes mellitus: an analysis from the UK NHS perspective

Exenatide 2 mg once-weekly is associated with a QALY gain of 0.102 compared to liraglutide 1.2 mg for treating type 2 diabetes.

• Exenatide 2 mg once-weekly showed a QALY gain per patient compared to other treatments: 0.046 vs dulaglutide 1.5 mg, 0.102 vs liraglutide 1.2 mg, 0.043 vs liraglutide 1.8 mg, and 0.074 vs lixisenatide 20 μg.
• The cost per patient for exenatide was lower than for liraglutide 1.8 mg by -£2,085, indicating it dominated this treatment.
• Cost differences per patient for exenatide compared to other treatments were £27 for dulaglutide 1.5 mg, £103 for liraglutide 1.2 mg, and £738 for lixisenatide 20 μg.
• The cost per QALY gained with exenatide was £596 compared to dulaglutide 1.5 mg, £1,004 compared to liraglutide 1.2 mg, and £10,002 compared to lixisenatide 20 μg.
• In probabilistic sensitivity analysis, the likelihood that exenatide is cost-effective ranged from 76% to 99%.

AI simplified